{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T04:30:10Z","timestamp":1778301010515,"version":"3.51.4"},"reference-count":14,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Pompe disease is a rare genetic disorder caused by a deficiency of a lysosomal enzyme called acid alpha-glucosidase and is classified into infantile and late-onset forms. Since 2006, an enzyme replacement therapy involving alglucosidase alfa has been available. In 2021, a new enzyme replacement therapy involving avalglucosidase alfa demonstrated improved clinical benefits. In this article, the authors describe the pharmacokinetics of avalglucosidase alfa using a population pharmacokinetic approach.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>The population pharmacokinetic model was developed using a data set that included 75 patients and 2042 plasma drug concentrations determined through enzymatic activity assay from 3 studies (phases I\/II and III) and involved 3 dose levels (5, 10, and 20 mg\/kg). The analysis was performed using NONMEM software.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Two sequences were observed in the plasma drug concentration profile: the first kinetic driving exposure, and after 12 hours postdose, a slight rebound addressing very low concentrations that lasted up to 2 weeks. Following model screening, a model with a central compartment with parallel linear and nonlinear elimination and 2 concatenated peripheral compartments was proposed. A putative back-redistribution of a marginal fraction of the drug from the second peripheral compartment to the central compartment may explain the slight rebound in concentration. The final model's mean bias and precision for individual predictions were \u22122.66% and 30.7%, respectively, and \u22120.433% and 38.9%, respectively, for population predictions.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>A concatenated 3-compartment model was developed to describe the avalglucosidase alfa concentrations in patients with late-onset Pompe disease. None of the covariates tested could explain the interindividual variability.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001086","type":"journal-article","created":{"date-parts":[[2023,8,9]],"date-time":"2023-08-09T18:00:10Z","timestamp":1691604010000},"page":"644-652","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Population Pharmacokinetic Modeling and Determination of Individual Exposure to Avalglucosidase Alfa in Adolescent and Adult Patients With Late-Onset Pompe Disease: Analysis of Pooled Data From Phase I to III Clinical Trials"],"prefix":"10.1097","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9858-8628","authenticated-orcid":false,"given":"Gilles","family":"Tuffal","sequence":"first","affiliation":[{"name":"Pharmacokinetics Dynamics and Metabolism, Translational Medicine and Early Development, Sanofi, Montpellier;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gilles","family":"Tiraboschi","sequence":"additional","affiliation":[{"name":"Pharmacokinetics Dynamics and Metabolism, Translational Medicine and Early Development, Sanofi, Montpellier;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabrice","family":"Hurbin","sequence":"additional","affiliation":[{"name":"Pharmacokinetics Dynamics and Metabolism, Translational Medicine and Early Development, Sanofi, Montpellier;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pascale","family":"Boittet","sequence":"additional","affiliation":[{"name":"Altran, B\u00e2timent Le Liner, P\u00e9rols, France; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel","family":"Palmer","sequence":"additional","affiliation":[{"name":"Biomarkers and Clinical Bioanalysis, Translational Medicine and Early Development, Sanofi, Framingham, Massachusetts."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Marie","family":"Martinez","sequence":"additional","affiliation":[{"name":"Pharmacokinetics Dynamics and Metabolism, Translational Medicine and Early Development, Sanofi, Montpellier;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Fabre","sequence":"additional","affiliation":[{"name":"Pharmacokinetics Dynamics and Metabolism, Translational Medicine and Early Development, Sanofi, Montpellier;"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2023,8,1]]},"reference":[{"key":"R1-20250603","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/mus.22329","article-title":"Consensus treatment recommendations for late-onset Pompe disease","volume":"45","author":"Cupler","year":"2012","journal-title":"Muscle Nerve."},{"key":"R2-20250603","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/01.gim.0000218152.87434.f3","article-title":"Pompe disease diagnosis and management guideline","volume":"8","author":"Kishnani","year":"2006","journal-title":"Genet Med."},{"key":"R3-20250603","doi-asserted-by":"crossref","first-page":"9181","DOI":"10.3390\/ijms22179181","article-title":"Enzyme therapy: current challenges and future perspectives","volume":"22","author":"de la Fuente","year":"2021","journal-title":"Int J Mol Sci."},{"key":"R7-20250603","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1021\/bc400365a","article-title":"Glycan structure determinants for cation-independent mannose 6-phosphate receptor binding and cellular uptake of a recombinant protein","volume":"24","author":"Zhou","year":"2013","journal-title":"Bioconjug Chem."},{"key":"R8-20250603","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1038\/mt.2009.37","article-title":"Glycoengineered acid alpha-glucosidase with improved efficacy at correcting the metabolic aberrations and motor function deficits in a mouse model of Pompe disease","volume":"17","author":"Zhu","year":"2009","journal-title":"Mol Ther."},{"key":"R9-20250603","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/S1474-4422(21)00241-6","article-title":"Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial","volume":"20","author":"Diaz-Manera","year":"2021","journal-title":"Lancet Neurol."},{"key":"R10-20250603","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.nmd.2018.12.004","article-title":"Safety, tolerability, pharmacokinetics, pharmacodynamics, and exploratory efficacy of the novel enzyme replacement therapy avalglucosidase alfa (neoGAA) in treatment-na\u00efve and alglucosidase alfa-treated patients with late-onset Pompe disease: a phase 1, open-label, multicenter, multinational, ascending dose study","volume":"29","author":"Pena","year":"2019","journal-title":"Neuromuscul Disord."},{"key":"R11-20250603","doi-asserted-by":"crossref","first-page":"e536","DOI":"10.1212\/WNL.0000000000200746","article-title":"NEO1 and NEO-EXT studies: long-term safety and exploratory efficacy of repeat avalglucosidase alfa dosing for 5.5 years in late-onset Pompe disease patients","volume":"99","author":"Dimachkie","year":"2022","journal-title":"Neurology"},{"key":"R12-20250603","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1023\/A:1011527125570","article-title":"Assessment of actual significance levels for covariate effects in NONMEM","volume":"28","author":"W\u00e4hlby","year":"2001","journal-title":"J Pharmacokinet Pharmacodyn."},{"key":"R13-20250603","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1023\/A:1020254823597","article-title":"Assessment of type I error rates for the statistical sub-model in NONMEM","volume":"29","author":"W\u00e4hlby","year":"2002","journal-title":"J Pharmacokinet Pharmacodynamics."},{"key":"R14-20250603","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0169-2607(98)00098-4","article-title":"A procedure for generating bootstrap samples for the validation of nonlinear mixed-effects population models","volume":"59","author":"Parke","year":"1999","journal-title":"Comput Methods Programs Biomed."},{"key":"R15-20250603","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1345\/aph.17304","article-title":"Statistical graphics in pharmacokinetics and pharmacodynamics: a tutorial","volume":"32","author":"Ette","year":"1998","journal-title":"Ann Pharmacother."},{"key":"R16-20250603","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s40262-018-0721-y","article-title":"Pharmacokinetic and pharmacodynamic modeling to optimize the dose of vestronidase alfa, an enzyme replacement therapy for treatment of patients with mucopolysaccharidosis type VII: results from three trials","volume":"58","author":"Qi","year":"2019","journal-title":"Clin Pharmacokinet."},{"key":"R18-20250603","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1177\/0091270007305299","article-title":"Enzyme replacement in Fabry disease: pharmacokinetics and pharmacodynamics of agalsidase alfa in children and adolescents","volume":"47","author":"Ries","year":"2007","journal-title":"J Clin Pharmacol."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001086","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T17:12:58Z","timestamp":1748970778000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FTD.0000000000001086"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,1]]},"references-count":14,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001086","relation":{},"ISSN":["0163-4356"],"issn-type":[{"value":"0163-4356","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8,1]]}}}